MedTrace Logo

Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy

NCT05315687 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2024-01-19

No results posted yet for this study

Summary

This phase II trial studies the effects of radioembolization with yttrium Y-90 works as a 2nd or 3rd line therapy for treating patients with breast cancer that has spread to the liver (metastatic to the liver). Yttrium Y-90 radioembolization is a therapy that injects radioactive particles directly into an artery that feeds liver tumors to cut off their blood supply.

Conditions

  • Anatomic Stage IV Breast Cancer AJCC v8
  • Metastatic Breast Carcinoma
  • Metastatic Carcinoma in the Liver
  • Prognostic Stage IV Breast Cancer AJCC v8

Interventions

DEVICE

Y-90 SIR-Spheres

Y-90 SIR-Spheres

PROCEDURE

Yttrium-90 Microsphere Radioembolization

Undergo Y90 radioembolization

OTHER

Systemic Therapy

Systemic Therapy

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Sirtex Medical

    collaborator INDUSTRY

  • Emory University

    lead OTHER

Principal Investigators

  • Nima Kokabi · Emory University Hospital/Winship Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-17
Primary Completion
2025-07-31
Completion
2025-07-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05315687 on ClinicalTrials.gov